Skip to main content
ASTAL LABORATORIES LIMITED logo

ASTAL LABORATORIES LIMITED — Investor Relations & Filings

Ticker · 512600 ISIN · INE307N01014 LEI · 8945004HO2WCBQ0CJ976 BSE.NS Manufacturing
Open in API
Filings indexed 435 across all filing types
Latest filing 2026-05-25 Regulatory Filings
Country IN India
Listing BSE.NS 512600

About ASTAL LABORATORIES LIMITED

https://miel.co.in/

Astal Laboratories Limited is a pharmaceutical organization engaged in the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations. The company's product portfolio encompasses various dosage forms, including tablets, capsules, liquid orals, and topical preparations. It operates across several therapeutic categories, such as anti-infectives, analgesics, and gastrointestinal treatments. Astal Laboratories prioritizes quality control and adheres to established manufacturing standards to ensure the safety and efficacy of its products. The company focuses on providing accessible healthcare solutions through a robust distribution network and a commitment to research-driven formulation development.

Recent filings

Filing Released Lang Actions
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve 1. To Consider and Approve ....
Regulatory Filings Classification · 85% confidence The document is a formal intimation to the stock exchange under SEBI Listing Regulations informing about a scheduled Board Meeting date and agenda (approval of audited results, appointment of auditors, etc.). It does not contain actual financial results nor is it a presentation or proxy. It is a generic regulatory announcement required by the exchange, fitting the fallback “Regulatory Filings” category.
2026-05-25 English
Outcome of Board meeting held today, 25th May, 2026.
Share Issue/Capital Change Classification · 95% confidence The document is a SEBI LODR Regulation 30 disclosure of the outcome of a board meeting approving the allotment of equity shares upon conversion of warrants, including detailed share allotment numbers, issue price, and post-allotment capital structure. This is an announcement of a new share issue/capital change rather than a full financial report or routine regulatory filing. Therefore, it fits the Share Issue/Capital Change category.
2026-05-25 English
Intimation of appointment of statutory auditor in material wholly owned subsidiary company to fill the casual vacancy due to resignation.
Regulatory Filings Classification · 80% confidence The document is a regulatory disclosure made under SEBI (Listing Obligations and Disclosure Requirements) Regulation 30 about the appointment of a statutory auditor of a material subsidiary. It contains no substantive financial statements or management/Q&A content, nor is it an AGM or earnings release. It is a compliance announcement, so it falls into the general Regulatory Filings category (RNS).
2026-05-20 English
Monitoring Agency report for the quarter ended 31st March, 2026.
Regulatory Filings Classification · 90% confidence The document is the full Monitoring Agency Report filed under Regulation 32 of SEBI LODR, providing detailed tables on utilization of preferential issue proceeds, agency declarations, issuer comments, and compliance data. It is not an earnings release, capital markets update announcement, or management/annual report itself, but a regulatory compliance filing. There is no specific category for Monitoring Agency Reports, so under the fallback for miscellaneous regulatory disclosures it falls under Regulatory Filings (RNS).
2026-05-15 English
Submission of intimation of resignation of statutory auditors of Sriven Pharmachem India Private limited a material subsidiary of the Company.
Regulatory Filings Classification · 82% confidence The document is an exchange filing under SEBI LODR regulations notifying the resignation of statutory auditors of a material subsidiary. It contains regulatory compliance disclosures rather than full financial statements or audit reports, and is not an announcement of dividend, management change, or capital action. This type of compliance/intimation filing falls under the general Regulatory Filings category (RNS).
2026-05-14 English
Submission of intimation of allotment of equity shares pursuant to conversion of warrants.
Share Issue/Capital Change Classification · 88% confidence The document is an SEBI (LODR) Regulation 30 intimation to the stock exchange informing about the Board meeting approval and allotment of new equity shares upon conversion of warrants. This constitutes a change in the company’s capital structure (new share issue). Therefore, it should be classified as a Share Issue/Capital Change.
2026-05-12 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.